文献速递心脑血管急症重症综合管理与镇静镇痛

药物性Toll样受体4抑制使星形胶质细胞A1/A2比值向有利方向偏移,改善创伤性脑损伤后的神经认知结局

Pharmacologic Toll-like receptor 4 inhibition skews toward a favorable A1/A2 astrocytic ratio improving neurocognitive outcomes following traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2023-01-19
一句话结论小鼠控制性皮质撞击模型显示,C34抑制TLR4可减少A1标志物、增加A2标志物表达,并改善神经认知结局。

本研究采用小鼠控制性皮质撞击创伤性脑损伤模型,设假手术组、假手术+C34组、TBI组和TBI+C34组,于伤后第1、7、28天分析。定量实时聚合酶链反应显示,伤后第1天C34治疗组A1标志物Gbp2表达显著降低、A2标志物Emp1表达显著升高;伤后第7、28天多数A1和A2标志物表达也显著降低。免疫组化显示C34治疗组至伤后第28天病灶内髓鞘碱性蛋白染色增加,Morris水迷宫显示伤后第7、28天C34治疗组平台进入次数更多。作者认为早期TLR4阻断使星形胶质细胞向抗炎A2样表型偏移,伴随髓鞘再生增加,提供更好神经保护并改善神经认知结局。

要点

  • 小鼠控制性皮质撞击TBI模型中,伤后第1天C34治疗组较未治疗组A1标志物Gbp2表达显著降低、A2标志物Emp1表达显著升高。
  • 伤后第7、28天,C34治疗组多数A1和A2标志物表达也显著降低。
  • 免疫组化显示C34治疗组至伤后第28天病灶内髓鞘碱性蛋白染色增加。
  • Morris水迷宫显示伤后第7、28天C34治疗组较未治疗组平台进入次数更多。
  • 作者认为早期TLR4阻断使星形胶质细胞向抗炎A2样表型偏移,是改善TBI后神经行为结局的潜在治疗靶点。

适用人群与场景

  • 小鼠控制性皮质撞击创伤性脑损伤模型,于伤后第1、7、28天分析。
  • 实验分组:假手术组、假手术+C34组、TBI组、TBI+C34组。

处置流程与药物剂量

  • C34为药物性Toll样受体4抑制剂,用于TBI后早期干预;原文未写明剂量、给药途径、频次和疗程。

研究设计与关键结果

  • 研究类型:小鼠控制性皮质撞击模型实验;分组为假手术组、假手术+C34组、TBI组、TBI+C34组,于伤后第1、7、28天分析。
  • 定量实时聚合酶链反应:伤后第1天,C34治疗组较未治疗组A1标志物Gbp2表达显著降低,A2标志物Emp1表达显著升高。
  • 伤后第7、28天,C34治疗组多数A1和A2标志物表达也显著降低。
  • 免疫组化:C34治疗组至伤后第28天病灶内髓鞘碱性蛋白染色增加。
  • Morris水迷宫:伤后第7、28天C34治疗组较未治疗组平台进入次数更多。
  • 统计学:采用Student t检验和单因素方差分析,p<0.05为差异有统计学意义。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠控制性皮质撞击模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,TBI后早期TLR4阻断可调节星形胶质细胞功能,使其向抗炎A2样表型偏移,伴随髓鞘再生增加,提供更好神经保护并改善神经认知结局。
  • 作者认为,以TLR4抑制靶向A1/A2平衡是改善TBI后神经行为结局的潜在治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Astrocytes are critical neuroimmune cells that modulate the neuroinflammatory response following traumatic brain injury (TBI) because of their ability to acquire neurotoxic (A1) or neuroprotective (A2) phenotypes. Using C34, a novel pharmacologic Toll-like receptor (TLR) 4 inhibitor, we explored their respective polarization states after TBI.

METHODS: A murine controlled cortical impact model was used, and the results were analyzed on postinjury days (PIDs) 1, 7, and 28. The experimental groups are as follows: (1) sham, (2) sham + C34, (3) TBI, and (4) TBI + C34. Quantitative real-time polymerase chain reaction was used to quantify gene expression associated with proinflammatory (A1) and anti-inflammatory (A2) phenotypes. Morris water maze was used to assess neurocognitive outcomes. Fixed frozen cortical samples were sectioned, stained for myelin basic protein and 4',6-diamidino-2-phenylindole, and then imaged. Student t test and one-way analysis of variance were used for statistical analysis with significance achieved when p < 0.05.

RESULTS: On quantitative real-time polymerase chain reaction, C34-treated groups showed a significant decrease in the expression of A1 markers such as Gbp2 and a significant increase in the expression of A2 markers such as Emp1 when compared with untreated groups on PID 1. On PIDs 7 and 28, the expression of most A1 and A2 markers was also significantly decreased in the C34-treated groups. On immunohistochemistry, C34-treated groups demonstrated increased myelin basic protein staining into the lesion by PID 28. C34-treated groups showed more platform entries on Morris water maze when compared with untreated groups on PID 7 and PID 28.

CONCLUSION: Following TBI, early TLR4 blockade modulates astrocytic function and shifts its polarization toward the anti-inflammatory A2-like phenotype. This is accompanied by an increase in myelin regeneration, providing better neuroprotection and improved neurocognitive outcomes. Targeting A1/A2 balance with TLR4 inhibition provides a potential therapeutic target to improve neurobehavioral outcomes in the setting of TBI.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. El Baassiri MG, Rahal SS, Fulton WB, et al. Pharmacologic Toll-like receptor 4 inhibition skews toward a favorable A1/A2 astrocytic ratio improving neurocognitive outcomes following traumatic brain injury. J Trauma Acute Care Surg. 2023. PMID: 36728129. doi:10.1097/TA.0000000000003887

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。